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Abstract Human Aurora-A is related to a protein kinase
originally identified by its close homology to Ipl1p from
Saccharomyces cerevisiae and aurora from Drosophila melano-
gaster, which are key regulators of the structure and function of
the mitotic spindle. We previously showed that human Aurora-A
is turned over through the anaphase promoting complex/
cyclosome (APC/C)^ubiquitin^proteasome pathway. The asso-
ciation of two distinct WD40 repeat proteins known as Cdc20
and Cdh1, respectively, sequentially activates the APC/C. The
present study shows that Aurora-A degradation is dependent on
hCdh1 in vivo, not on hCdc20, and that Aurora-A is targeted for
proteolysis through distinct structural features of the destruction
box, the KEN box motifs and its kinase activity. / 2002 Fed-
eration of European Biochemical Societies. Published by Else-
vier Science B.V. All rights reserved.
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1. Introduction
The most studied kinase of M-phase progression is cyclin-
dependent kinase 1 (Cdk1). In addition to Cdk1, the polo-like
kinases, as well as the NimA-related (NEK), Bub1, LATS and
Aurora families are implicated in a variety of mitotic process-
es, such as centrosome separation, chromosome segregation
and cytokinesis [1]. The ¢rst members of the Aurora family to
be identi¢ed were the serine/threonine kinases, budding yeast
Ipl1p and Drosophila aurora, which are required for chromo-
some segregation, centrosome maturation and function of the
mitotic spindle [2,3]. Three genes in human and mouse, two
each in the £y, frog and worm, and one in budding yeast
encode the Aurora family of protein kinases. Human
Aurora2/Aik/STK15/BTAK/ARK1/AIRK and mouse IAK1/
Ayk1 appear to constitute a subfamily, because these protein
kinases have closely related N-terminal as well as C-terminal
kinase domains. Herein we refer to these proteins as Aurora-A
according to the recommended nomenclature [1,4]. Aurora-A
localizes to mitotic structures such as centrosomes and spin-
dle poles, and both the message and protein levels are cell-
cycle regulated [5^9]. The Xenopus kinesin-related protein
Eg5 [10] and the cytoplasmic polyadenylation element-binding
factor [11] are putative substrates of Xenopus Aurora-A/Eg2,
but in mammals the physiological substrates and upstream
regulators of Aurora-A remain unknown. Human Aurora-A
is ampli¢ed in several human cancers [5,12^14] and Aurora-A
overexpression causes malignant transformation in cultured
cells [5,12]. These ¢ndings suggest that Aurora-A protein is
important for the proliferation and genomic integrity of hu-
man cells.
The ubiquitin-proteasome pathway plays an important role
in various cellular processes, including cell-cycle regulation,
signal transduction, di¡erentiation, antigen processing and
degradation of tumor suppressors [15]. The ubiquitin protein
ligase (E3) catalyzes the covalent attachment of polyubiquitin
chains priming substrates for degradation by proteasomes.
Two E3s play a role in the cell cycle: the anaphase promoting
complex/cyclosome (APC/C) and the SCF (Skp1, cullin,
F-box) complex [16]. The APC was the ¢rst multisubunit E3
to be described and is required for the degradation of cyclin B
and sister chromatid separation [17^19]. The APC/C-depen-
dent degradation requires the conserved activators, Cdc20/
p55CDC/Fizzy and Cdh1/Hct1/Fizzy-related. These two classes
of proteins containing WD40 repeats bind to the APC/C and
act as substrate recognition subunits, although it is not clear
whether these APC/C activators regulate the activity and sub-
strate speci¢city of the APC/C [18^22]. Two important de-
struction signals have been identi¢ed in substrates targeted
for destruction by the APC/C, the destruction box and the
KEN box. Cdc20-APC/C requires the destruction box. Muta-
tions in the destruction box stabilize cyclins and signi¢cantly
reduce or abolish their ubiquitination [23]. The KEN box is
the transportable degradation signal of human Cdc20 for
Cdh1-APC/C that has been identi¢ed using in vitro ubiquiti-
nation and proteolysis assays [24]. The KEN box is necessary,
but not su⁄cient by itself to target human Cdc6, securin/pi-
tuitary tumor transforming gene (PTTG) and other proteins
required for destruction in vivo [25^30].
2. Materials and methods
2.1. Materials
N-Acetyl-Leu-Leu-norleucinal (LLnL) was purchased from Sigma
and used at a ¢nal concentration of 25 WM. Polyclonal anti-MAPK
antibody was obtained from Cell Signaling Technology. Monoclonal
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anti-cyclin B1 and anti-glutathione S-transferase (GST) antibodies
were obtained from Santa Cruz and Amersham Biosciences, respec-
tively. Anti-glu and anti-myc monoclonal antibodies were gifts from
Dr. Larry A. Feig (Tufts University, Boston, MA, USA). Anti-
Aurora-A monoclonal antibody (M11-17) has been described [9].
The monoclonal antibody K3-7 was raised against a recombinant
GST-tagged Aurora-A [9] that recognizes the kinase domain of the
Aurora family. Antibody speci¢city was tested by immunoblotting.
2.2. Plasmid Constructs
Complementary DNAs corresponding to the human Cdc20 [acces-
sion no. AF099644.1], Cdh1 [accession no. AF083810.1] and PTTG
[accession no. AJ223953.1], were obtained by the reverse transcrip-
tion-polymerase chain reaction (PCR) using total RNA from DLD-1
colon cancer cells [9]. We created a mammalian expression vector by
inserting cDNA into an altered version of pMT3 that contained a
modi¢ed glu (MEFMPME) 5P of the cloning site [31] or into myc/
pcDNA3 (Invitrogen). The plasmids, glu-Aurora-A/pMT3, Aurora-A/
pGEX4T-2 and mammalian GST expression pME4T-2 have been
described [9,32]. Point mutations within Aurora-A were engineered
by standard double PCR mutagenesis. All PCR-ampli¢ed cDNA
products were con¢rmed by sequencing.
2.3. Cell-cycle synchronization
HeLa cells were maintained in Dulbecco’s modi¢ed Eagle’s medium
(DMEM) supplemented with 10% fetal calf serum (FCS; Sigma).
Tissue culture dishes (10 cm) were seeded at a density of 3U106
with exponentially growing HeLa cells. The cells were then synchron-
ized at S-phase using a double exposure to thymidine as follows [9].
On the day after seeding, thymidine (Sigma) was added to the medium
at a ¢nal concentration of 2.5 mM and the plates were incubated for
16 h at 37‡C. The plates were then washed three times with phos-
phate-bu¡ered saline (PBS), then the cells were incubated in normal
growth medium for 8 h at 37‡C. Thereafter, the cells were incubated
with thymidine again for 16 h. The cells were washed three times with
PBS to remove the thymidine and normal growth medium was added.
We monitored cell-cycle distribution by staining cellular DNA with
propidium iodide then analyzing the cells with a FACScan (Becton
Dickinson).
2.4. Transient transfection
COS-7 cells were maintained in DMEM supplemented with 10%
FCS. COS-7 cells (3U105 cells in a 60 mm culture dish) were trans-
fected using DEAE-Dextran [31].
2.5. In vivo degradation assay
Total cell lysates were prepared from COS cells transfected with
1 Wg of glu-Aurora-A alone or together with the indicated amounts
of myc-hCdc20 or myc-hCdh1. Empty vector myc/pcDNA3 was
added to 3 Wg of DNA. COS cells were incubated in the presence
(+) or absence (^) of proteasome inhibitor LLnL for 10 h, then
Aurora-A expression was measured by immunoblotting with anti-
glu mAb. Levels of proteins containing WD repeats were measured
by immunoblotting with anti-myc.
3. Results and discussion
3.1. Expression of human Aurora proteins is cell-cycle
dependent
Mammals possess at least Aurora-A, -B and -C [4], which
are cell-cycle regulated [5^7,9,33,34]. To further examine en-
dogenous Aurora-A expression with respect to other Aurora
proteins during di¡erent phases of the cell cycle, we raised the
monoclonal antibody K3-7 against recombinant GST-tagged
full-length human Aurora-A. This antibody cross-reacted with
Aurora-B and Aurora-C recognizing the kinase domain of the
Aurora family but not that of other kinases such as MAPK
(data not shown). HeLa cells were synchronized by double
thymidine block then released from G1/S boundary. Human
Aurora proteins were immunoblotted on the same membrane
Fig. 1. Cell-cycle dependent protein expression of Aurora family. HeLa cells were synchronized at G1/S boundary by double thymidine block,
then cells were collected at indicated times after release from arrest. Protein levels of Aurora family, cyclin B and MAPK were determined by
immunoblotting with anti-pan Aurora (upper panel), anti-cyclin B (middle panel), or with anti-MAPK antibodies (lower panel), respectively.
Cell-cycle synchronization was con¢rmed by £ow cytometry (data not shown).
C
Fig. 2. Expression of hCdh1 decreases steady-state level of Aurora-A in vivo. a: Increasing amounts of hCdh1 correlate with decreased
Aurora-A expression. Total cell lysates were prepared from COS cells transfected with 1 Wg of glu-Aurora-A alone (lane 1) or together with 0.5
and 2 Wg of myc-hCdc20 (lanes 2 and 3) or myc-hCdh1 (0.5 and 2 Wg, lanes 5 and 6). Empty vector (myc/pcDNA3) was added to 3 Wg of
DNA. COS cells were incubated in the presence (+) or absence (^) of proteasome inhibitor LLnL for 10 h, then Aurora-A expression was mea-
sured by immunoblotting with anti-glu mAb (upper panel). Levels of proteins containing WD repeats were measured by immunoblotting with
anti-myc (middle panel). b: Both hCdc20 and hCdh1 decrease steady-state level of hPTTG. Proteins levels of hPTTG were determined in COS
cells transfected with myc-tagged hPTTG and increasing concentrations of myc-hCdc20 or myc-hCdh1. Amounts of DNA are shown in micro-
grams. Empty vector myc/pcDNA3 was added to 3 Wg of DNA. c: Neither hCdc20 nor hCdh1 a¡ects steady-state levels of GST. COS cells
were transfected with GST expression plasmid pME4T-2 (1 Wg) together with increasing amounts of myc-hCdc20 (lanes 2^4) or myc-hCdh1
(lanes 6^8). Transfected cells were incubated for 10 h in either the presence (+) or absence (^) of LLnL prior to lysis. Immunoblots of total cel-
lular lysates were probed with anti-GST (upper panel), anti-myc (middle panel), or anti-MAPK (lower panel) antibodies. d: The in vivo degra-
dation assay using S- and M-phase synchronized cells. COS cells were transfected with 1 Wg of glu-Aurora-A alone or together with 0.5 and
2 Wg of myc-hCdh1. The cells were then synchronized at S-phase using a single exposure to thymidine for 14 h or at M-phase by nocodazole
(400 ng/ml) for 12 h. COS cells were incubated in the presence (+) or absence (^) of proteasome inhibitor LLnL for 10 h, then Aurora-A ex-
pression was measured by immunoblotting with anti-glu mAb (upper panel).
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using HeLa cell lysates. Consistent with the earlier ¢ndings,
Aurora-A protein was absent through G1, began to accumu-
late in S-phase, and peaked late in mitosis (Fig. 1, upper
panel). Endogenous Aurora-A was expressed in a manner
similar to that of cyclin B (Fig. 1, middle panel). Although
the expression level of Aurora-B and Aurora-C proteins oscil-
lated, Aurora-B and Aurora-C were expressed for a longer
period than Aurora-A (Fig. 1, upper panel). In particular,
the levels of Aurora-B and of Aurora-C remained obvious
during S- and early G1-phase, respectively. The control
MAPK protein level did not signi¢cantly change during cell-
cycle progression (Fig. 1, lower panel).
3.2. Degradation of Aurora-A by hCdh1 in vivo, but not by
hCdc20
We have shown that Aurora-A is turned over through the
APC/C^ubiquitin^proteasome pathway [9]. Activation of the
APC/C requires association with the WD-repeat protein,
Cdc20 or Cdh1 [18,19]. In this regard, Cdc20 interacts with
Aurora-A in both Xenopus egg extracts and human cells [35].
We therefore investigated which WD-repeat protein activates
APC/C for Aurora-A degradation in vivo. Aurora-A co-ex-
pressed with hCdh1 in COS cells produced a signi¢cant, dose-
dependent decrease in the steady-state levels of Aurora-A pro-
tein (Fig. 2a, compare lane 1 to lanes 5 and 6), while the
Fig. 3. Kinase activity of Aurora-A does not a¡ect its degradation. COS cells were transfected with expression plasmids (1 Wg) for glu-Aurora-A
(lanes 1^4) or glu-Aurora-A (KN) (lanes 5^8) together with increasing amounts of myc-hCdc20 (a) or myc-hCdh1 (b). Transfected cells were
incubated for 10 h in either the presence (+) or absence (^) of LLnL prior to lysis. Immunoblots of total cellular lysates were probed with
anti-glu (upper panel), anti-myc (middle panel), or anti-MAPK (lower panel) antibodies.
C
Fig. 4. KEN box and destruction box-like motifs in Aurora-A are not signals for degradation. a: Wild-type or KEN box mutant (KEN-A)
forms of Aurora-A (glu-tagged) with indicated amounts of myc-hCdh1 were transiently expressed in COS cells. b: COS cells were transfected
with cDNA encoding glu-Aurora-A or glu-Aurora-A (D2ms) together with indicated amounts of myc-hCdh1. c: Wild-type or KEN box/de-
struction box double mutant (KEN-A/D2ms) forms of Aurora-A (glu-tagged) with indicated amounts of myc-hCdh1 were transiently expressed
in COS cells. Transfected cells were incubated for 10 h in either the presence (+) or absence (^) of 25 WM LLnL. Immunoblots of total cellular
lysates were probed with anti-glu (upper panel), anti-myc (middle panel), or anti-MAPK (lower panel) antibodies. d: Wild-type or KEN box/
destruction box double mutant (KEN-A/D2ms) forms of Aurora-A with indicated amounts of myc-hCdh1 were transiently expressed in COS
cells. Levels of Aurora-A, myc-hCdh1 and MAPK were determined by immunoblotting with anti-Aurora-A (upper panel), anti-myc (middle
panel), or with anti-MAPK antibodies (lower panel), respectively.
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MAPK protein level did not signi¢cantly change, thus con-
¢rming that protein loading was comparable. This conse-
quence was speci¢c to hCdh1 because hCdc20 overexpression
did not a¡ect Aurora-A protein (Fig. 2a, lanes 1 to 3). The
proteasome inhibitor LLnL restored hCdh1-dependent de-
creases in Aurora-A (Fig. 2a, compare lanes 6 and 7). Thus,
the hCdh1-mediated down-regulation of Aurora-A was not
caused by a decrease in its synthesis rate, but by accelerated
turnover through proteasomes.
To rule out the possibility that hCdc20 cannot function in
this system, we tested whether hCdc20 regulates steady-state
levels of hPTTG, which is degraded by proteolysis mediated
by the APC/C in a manner that is dependent on destruction
and KEN boxes [26]. We transfected COS cells with a ¢xed
amount of hPTTG and varying amounts of proteins contain-
ing WD repeats. Levels of hCdh1 or hCdc20 in the extracts
increased in concert with a signi¢cant, dose-dependent de-
crease in steady-state levels of hPTTG protein (Fig. 2b).
The proteasome inhibitor LLnL inhibited the decreases in
hPTTG expression by both hCdc20 and hCdh1 (Fig. 2b, lanes
4 and 7). Therefore, both hCdc20 and hCdh1 mediate degra-
dation of hPTTG in this system. In contrast, neither hCdc20
nor hCdh1 in£uenced steady-state levels of GST (Fig. 2c).
These ¢ndings demonstrated that the speci¢cities of the
hCdc20- and hCdh1-activated forms of APC/C di¡ered in
the in vivo degradation system and that Aurora-A degrada-
tion is mediated by hCdh1, but not by hCdc20.
The level of hCdc20 is cell-cycle regulated with a peak in
G2/M-phase, but its ability to activate the APC/C appears to
be limited by the prior phosphorylation of APC/C core sub-
units by both Cdk and polo-like kinases. In contrast to
hCdc20, hCdh1 is expressed throughout the cell cycle but
Cdk-dependent phosphorylation of hCdh1 prevents it from
binding to the APC/C core particle until late anaphase. In
addition to phosphorylation, both hCdc20- and hCdh1-depen-
dent APC/C activations are regulated by Mad2 (and its re-
lated protein Mad2b) in response to the mitotic checkpoint
signals [16,18,19]. It is not clear whether the increment of
hCdh1 is enough for Aurora-A degradation. To address
this, we performed the in vivo degradation experiments using
S- and M-phase synchronized cells. hCdh1-dependent de-
creases of Aurora-A in non-treated COS cells and in thymi-
dine treated COS cells were comparable (Fig. 2d, lanes 1^4
and 9^12). In contrast to S-phase synchronized cells, hCdh1
did not signi¢cantly in£uence steady-state levels of Aurora-A
protein in nocodazole-treated COS cells (Fig. 2d, lanes 5^8).
Cdk1 kinase activity is a peak at the prometaphase, thereby
inhibiting hCdh1 binding to the APC/C core particle despite
the increased hCdh1 levels. These data suggest that Aurora-A
is degraded in late anaphase. This assay is useful because it
can test the e¡ect of speci¢c factors such as drugs, DNA
damage, or co-transfection with other genes.
To re-examine the association of Aurora-A with hCdc20 or
hCdh1, we transfected myc-tagged hCdc20 or hCdh1 expres-
sion vector with glu-Aurora-A into COS cells with or without
LLnL. Glu-Aurora-A immunoprecipitates contained neither
hCdc20 nor hCdh1 (data not shown). Aurora-A binding to
hCdc20 or hCdh1 was undetectable, possibly because the af-
¢nity was too low to measure.
3.3. Aurora-A kinase activity does not a¡ect its degradation
Phosphorylation and dephosphorylation exquisitely regu-
late APC/C activity [1]. Furthermore, Aurora family kinases
form complexes with the protein serine/threonine phospha-
tases that regulate the kinase activation of Aurora families
[32,36]. Therefore we examined whether Aurora-A kinase ac-
tivity a¡ects its degradation. We prepared a catalytically in-
active mutant of human Aurora-A, in which an invariant
lysine residue (K162) was replaced with arginine in the
ATP-binding motif of the catalytic domain [37]. Fig. 3 shows
that the kinase-de¢cient mutant was also degraded upon co-
expression with hCdh1, but not with hCdc20. These experi-
ments showed that Aurora-A kinase activity is not required
for its own destruction and that other sequences are involved
in its degradation.
3.4. The KEN box in Aurora-A is not a signal for degradation
Aurora-A lacks a functional destruction box [9] so the deg-
radation signal is recognized by hCdh1-APC through other
structural features. The KEN box (composed of the amino
acids K-E-N) is an hCdh1-APC recognition signal distinct
from the destruction box [24]. Aurora-A has KEN residues
at the extreme amino terminus, position 5^7. The KEN box-
like motif is not evolutionarily conserved in the Aurora fam-
ily, even in human Aurora-C [38]. To investigate whether the
KEN box in Aurora-A serves as a functional signal for deg-
radation, we constructed a derivative of Aurora-A (Aurora-
AKENA) in which the invariant KEN residues were changed
to alanines within the full-length protein. The KEN box mu-
tant was also degraded by co-expression with hCdh1 (Fig. 4a).
We have previously demonstrated that one stretch
(205RVYLILEYA) similar to the destruction box in Aurora-
A might serve as a signal for polyubiquitination, but that this
stretch alone was not su⁄cient to act as the degradation sig-
nal [9]. We then tested the stability of two mutants, one in the
destruction box like stretch (D2ms) and a second with both a
D2ms and KEN-A mutation. Fig. 4b,c shows that hCdh1
overexpression also leads to degradation of these Aurora-A
proteins. To rule out any e¡ects of the epitope tag, we per-
formed a similar experiment using untagged Aurora-A. The
hCdh1 degradative phenotype of cells transfected with wild or
mutant Aurora-A (untagged) was the same as that caused by
the glu-tagged versions (Fig. 4d). These results suggested that
the KEN box and the destruction box-like motifs in Aurora-A
are not signals for degradation in vivo. In summary, the rapid
loss of human Aurora-A at the end of mitosis is due to pro-
tein degradation targeted by the hCdh1-APC/C^ubiquitin^
proteasome pathway through other structural features func-
tioning as the degradation signal.
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